Back to top
more

Pediatrix Medical Group, Inc. (MD)

(Real Time Quote from BATS)

$8.00 USD

8.00
54,894

+0.32 (4.17%)

Updated Jul 25, 2024 10:40 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 250)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why You Should Retain MEDNAX (MD) in Your Portfolio

by Zacks Equity Research

Riding high on its revenue stream and strategic measures, MEDNAX (MD) holds potential to reap benefits for investors.

MEDNAX's (MD) Earnings Beat Estimates in Q2, Improve Y/Y

by Zacks Equity Research

MEDNAX's (MD) Q2 results reflect solid volumes, partly offset by escalating expenses.

Mednax (MD) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Mednax (MD) delivered earnings and revenue surprises of 24.24% and 3.72%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Mednax (MD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Mednax (MD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Humana (HUM) to Announce Q2 Earnings: Here's What to Expect

by Zacks Equity Research

Humana's (HUM) second-quarter earnings results to reflect a steep expense level, partly offset by better revenues.

HCA Healthcare's (HCA) Q2 Earnings and Revenues Top Estimates

by Zacks Equity Research

HCA Healthcare's (HCA) Q2 earnings gain traction from higher revenues and improved admissions.

What's in the Cards for HCA Healthcare's (HCA) Q2 Earnings?

by Zacks Equity Research

HCA Healthcare's (HCA) second-quarter earnings are likely to have gained from better revenues.

Down 11.6% in 4 Weeks, Here's Why Mednax (MD) Looks Ripe for a Turnaround

by Zacks Equity Research

Mednax (MD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

UnitedHealth (UNH) Beats on Q2 Earnings, Hikes '21 EPS View

by Zacks Equity Research

UnitedHealth Group's (UNH) second-quarter 2021 results reflect improving revenues resulting in top-line growth at both the business units, partly offset by higher costs.

Why Should You Hold HCA Healthcare (HCA) in Your Portfolio?

by Zacks Equity Research

Riding high on growth measures and a solid 2021 guidance, HCA Healthcare (HCA) holds enough potential to reap benefits for investors.

Tenet Healthcare (THC) to Divest Hospitals for $1.1 Billion

by Zacks Equity Research

Tenet Healthcare (THC) to sell five hospitals to Steward Health Care System, LC for a deal value of $1.1 billion.

Tenet Healthcare (THC) Soars 69% YTD: More Room to Run?

by Zacks Equity Research

Banking high on a solid guidance and strategic measures, Tenet Healthcare (THC) holds enough potential to reap benefits for investors.

    Community Health (CYH) Soars 111% YTD: More Room to Run?

    by Zacks Equity Research

    Community Health's (CYH) strategic initiatives are likely to boost its revenues, which in turn, might perk up its share price.

    MEDNAX's (MD) Q1 Earnings Surpass Estimates, Decline Y/Y

    by Zacks Equity Research

    MEDNAX's (MD) Q1 results reflect lower costs. However, the same is partly offset by softer revenues.

    Mednax (MD) Q1 Earnings and Revenues Beat Estimates

    by Zacks Equity Research

    Mednax (MD) delivered earnings and revenue surprises of 60.00% and 2.36%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

    Sapna Bagaria headshot

    Healthcare Stock Q1 Earnings Due on May 7: ELAN, MD, MODV

    by Sapna Bagaria

    Varied companies across the vast healthcare space might have been affected differently by the COVID crisis during the first quarter.

    Earnings Preview: Mednax (MD) Q1 Earnings Expected to Decline

    by Zacks Equity Research

    Mednax (MD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Here's Why You Should Retain Mednax (MD) in Your Portfolio

    by Zacks Equity Research

    Riding high on strategic initiatives and telehealth medicine, MEDNAX (MD) holds potential to reap benefits for investors.

    Mednax (MD) Up 31.6% Since Last Earnings Report: Can It Continue?

    by Zacks Equity Research

    Mednax (MD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    Mednax (MD) Ties Up With NightLight to Offer Better Pediatric Care

    by Zacks Equity Research

    Mednax (MD) collaborates with NighLight with an aim to offer enhanced pediatric care in Texas.

    Tenet Healthcare (THC) Hits 52 Week High: Will the Rally Stay?

    by Zacks Equity Research

    Tenet Healthcare's (THC) shares display an upsurge as investors get optimistic about its latest strategic initiatives and cost-curbing measures.

    Why Should You Add Community Health (CYH) to Your Portfolio?

    by Zacks Equity Research

    Riding high on telehealth services and cost-cutting measures, Community Health (CYH) holds potential to reap benefits for investors.

    MEDNAX's (MD) Q4 Earnings Fall Shy of Estimates, Tumble Y/Y

    by Zacks Equity Research

    MEDNAX's (MD) fourth-quarter results reflect muted revenues caused by the COVID-19 pandemic.

    Mednax (MD) Q4 Earnings and Revenues Miss Estimates

    by Zacks Equity Research

    Mednax (MD) delivered earnings and revenue surprises of -19.35% and -8.64%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

    Here's Why You Should Hold MEDNAX (MD) in Your Portfolio Now

    by Zacks Equity Research

    Riding high on its strategic efforts and cost-cutting measures, MEDNAX (MD) holds enough potential to reap benefits for investors.